ACRS News and Press, Aclaris Therapeutics Inc. From 04/24/23

2023-04-24 14:37:47 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips In a high-interest-rate environment, cash is king. All biotech companies will need to continue spending to finance their R&D. But debt-fueled spending is becoming expensive. And selling sto...

2023-04-12 17:16:26 ET Gainers: Dragonfly Energy Holdings  ( DFLI ) +5% . C4 Therapeutics ( CCCC ) +5% . Sana Biotechnology ( SANA ) +4% . SunPower Corporation ( SPWR ) +3% . Cogent Biosciences ( COGT ) +3% . Losers: ...

WAYNE, Pa., March 27, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a fire...

2023-03-09 07:30:00 ET Summary Aclaris Therapeutics reported disappointing marks for zunsemetinib’s “ATI-450” Phase IIa trial for moderate to severe hidradenitis suppurativa. The share price has been nearly chopped in half. The trial missed the primary and sec...

2023-03-06 17:51:13 ET The major U.S. equity averages posted a mixed performance on Monday, holding steady after the gains recorded at the end of last week. Wall Street looked ahead to an appearance by Federal Reserve Chair Jerome Powell, who is scheduled to appear before Congress starting ...

2023-03-06 14:32:00 ET The stock market got off to a solid start on Monday, although there was a considerable disparity among different kinds of stocks. Small-cap indexes were down sharply, but the Dow Jones Industrial Average (DJINDICES: ^DJI) was higher by about a quarter-percent ...

2023-03-06 13:05:55 ET Gainers: Bellerophon ( BLPH ) +86% . Ambrx Biopharma ( AMAM ) +69% . BridgeBio Pharma ( BBIO ) +56% . Avalon GloboCare ( ALBT ) +47% . Azul ( AZUL ) +42% . TCR2 Therapeutics ( TCRR ) +38% . ...

2023-03-06 11:50:33 ET Shares of Aclaris Therapeutics (NASDAQ: ACRS) were crashing 41.7% lower as of 11:29 a.m. ET on Monday. The huge decline came after the company announced preliminary top-line results from a phase 2a clinical study evaluating zunsemetinib (ATI-450) in treating m...

2023-03-06 10:00:19 ET Gainers: BridgeBio Pharma ( BBIO ) +67% . Armata Pharmaceuticals ( ARMP ) +23% . TCR2 Therapeutics ( TCRR ) +21% . Euda Health ( EUDA ) +12% . Kala Pharmaceuticals ( KALA ) +16% . Losers: Aclaris...

2023-03-06 08:36:42 ET Aclaris Therapeutics ( NASDAQ: ACRS ) oral drug zunsemetinib (ATI-450) did not meet the main goal of a phase 2a trial in patients with with moderate to severe hidradenitis suppurativa (HS). HS is a condition which causes small, painful lumps ...